Table 2.
Results of single sequences based on multiple volumetric interests for predicting MVI
| Sequence | Classifier and cohort | AUC | ||||||
|---|---|---|---|---|---|---|---|---|
| VOI50% | VOItumor | VOItumor + 5mm | VOItumor + 10mm | VOItumor + liver | VOItumor + 5mm + liver | VOItumor + 10mm + livera | ||
| T2WI | RF (TD/VD) | 0.818/0.722 | 0.832/0.714 | 0.897/0.730 | 0.816/0.742 | 0.841/0.726 | 0.867/0.749 | 0.975/0.755 |
| LR (TD/VD) | 0.641/0.698 | 0.647/0.708 | 0.632/0.725 | 0.650/0.712 | 0.647/0.708 | 0.632/0.725 | 0.638/0.727 | |
| DWI | RF (TD/VD) | 0.830/0.736 | 0.980/0.778 | 0.879/0.793 | 0.828/0.791 | 0.813/0.784 | 0.832/0.793 | 0.978/0.812 |
| LR (TD/VD) | 0.695/0.701 | 0.752/0.703 | 0.663/0.775 | 0.655/0.777 | 0.681/0.731 | 0.664/0.774 | 0.667/0.780 | |
| PRE | RF (TD/VD) | 0.829/0.737 | 0.938/0.765 | 0.898/0.771 | 0.813/0.761 | 0.991/0.782 | 0.878/0.797 | 0.912/0.810 |
| LR(TD/VD) | 0.746/0.749 | 0.730/0.752 | 0.728/0.757 | 0.728/0.757 | 0.730/0.761 | 0.730/0.773 | 0.735/0.782 | |
| Pre-T1 maps | RF (TD/VD) | 0.802/0.793 | 0.720/0.714 | 0.642/0.738 | 0.669/0.758 | 0.677/0.717 | 0.826/0.740 | 0.752/0.766 |
| LR(TD/VD) | 0.633/0.765 | 0.658/0.724 | 0.643/0.714 | 0.631/0.746 | 0.648/0.715 | 0.652/0.714 | 0.637/0.754 | |
| AP | RF (TD/VD) | 0.980/0.685 | 0.873/0.765 | 1.000/0.812 | 0.996/0.802 | 0.948/0.777 | 0.886/0.815 | 0.944/0.830 |
| LR (TD/VD) | 0.701/0.692 | 0.715/0.693 | 0.686/0.746 | 0.731/0.742 | 0.639/0.719 | 0.821/0.761 | 0.715/0.761 | |
| PVP | RF (TD/VD) | 0.920/0.740 | 0.996/0.810 | 0.876/0.832 | 0.808/0.818 | 0.902/0.825 | 0.902/0.836 | 0.912/0.837 |
| LR (TD/VD) | 0.761/0.706 | 0.755/0.768 | 0.728/0.798 | 0.731/0.799 | 0.733/0.796 | 0.732/0.800 | 0.727/0.806 | |
| TP | RF (TD /VD) | 0.900/0.729 | 0.963/0.728 | 0.995/0.738 | 0.854/0.778 | 0.884/0.749 | 0.871/0.762 | 0.802/0.792 |
| LR (TD /VD) | 0.716/0.683 | 0.718/0.716 | 0.720/0.707 | 0.739/0.754 | 0.720/0.725 | 0.736/0.720 | 0.751/0.762 | |
| HBP | RF (TD/VD) | 0.712/0.784 | 0.991/0.799 | 0.874/0.831 | 0.976/0.789 | 1.000/0.808 | 0.866/0.827 | 0.885/0.855 |
| LR (TD/VD) | 0.676/0.723 | 0.744/0.746 | 0.678/0.735 | 0.770/0.759 | 0.743/0.762 | 0.751/0.803 | 0.715/0.805 | |
| HBP-T1 maps | RF (TD/VD) | 0.923/0.718 | 0.808/0.705 | 0.821/0.726 | 0.821/0.726 | 0.822/0.724 | 0.822/0.729 | 0.807/0.731 |
| LR (TD/VD) | 0.705/0.703 | 0.706/0.703 | 0.691/0.708 | 0.684/0.715 | 0.683/0.714 | 0.705/0.715 | 0.702/0.716 | |
Abbreviations: VOI, volumetric interest; AUC, area under the curve; VD, validation dataset; TD, training dataset; RF, random forest; LR, logistic regression; T2WI, T2-weighted imaging with fat suppression; DWI, diffusion-weighted imaging; PRE, pre-contrast phase; AP, arterial phase; PVP, portal venous phase; TP, transitional phase; HBP, hepatobiliary phase
a The sensitivity, specificity, and AUC of VOItumor + 10mm + liver using random forest in each single sequence for predicting histologic MVI are listed in Table S4
Italicized values indicated the highest AUC of validation cohort in each single sequence